Latest MND Webinar information on Monepantel, page-34

Thanks for the concise and systematic point by point study @kpax. Going by your analysis, CNM-Au8 is very much a work in progress, unlike our monepantel pill - which has a fast-acting and very effective role in up-regulating the autophagy process that is needed as part of the treatment of MND/ALS, and most probably of other neurodegenerative diseases and a number of cancers (the latter is already proven in the lab with 28 types of human tumours) - something PharmAust needs to highlight to the investing public. PharmAust's monepantel pill, with its proven up-regulation of the much needed autophagy process with minimal side effects, is the current global gold standard for this purpose, and fearing that some highly specialised treatment like CNM-Au8 is going to suddenly make it redundant is mistaken (or so it seems to me).

Cheers